Abstract: Described are compositions and methods for the treatment of acne. The method and compositions comprise an orally ingested composition containing thymic peptides, vitamins, and minerals. Zinc, pantothenic acid, magnesium, pyridoxine, vitamins A and D, riboflavin, and folic acid are found to be essential to the composition. Also described is a topical composition comprising pantothenic acid that, when used in conjunction with the oral composition, resulted in a better response than either the oral or topical composition alone.

Abstract: The present invention relates to a pharmaceutical composition based on a petasites extract without a hepatoxic, carcinogenic, cytostatic and/or mutagenic effect, the use thereof and a method for the production thereof.

Abstract: A method for treating a skin condition by intimately combining a water soluble antibiotic with the keratin layer of the outermost layer of the cleansed epidermis. The antibiotic is dissolved in the alkaline fraction of an electrolyzed water. The solution is characterized by the absence of hydrolysis products, turbidity, and loss of potency of the antibiotic. The aqueous solution is applied to the treatment area where the water is absorbed by the keratin and the antibiotic is carried into intimate contact with the keratin after which the water is evaporated leaving the antibiotic dispersed across the treatment area.

Abstract: The present invention provides for the treatment of an individual suffering from lupus erythematosus utilizing a serine protease inhibitor. The treatment includes the use of a corticosteroid that is administered separately or in combination. The serine proteases preferred are alpha 1-antitrypsin, secretory leucocyte protease inhibitor, alpha 2-macroglobulin or mixtures thereof.

Abstract: A method for reducing the production of malodor in sulfur containing dermatological compositions by adjusting the pH of the composition to between about 6.5 to about 8.1. Also, sulfur containing dermatological compositions having a pH between about 6.5 and about 8.1.

Abstract: Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.

Abstract: The invention concerns a method for preparing aloin which consists in extracting from a substance containing aloe, in particular the yellow sap of aloe or a derived product, in the presence of an aliphatic diol or triol with low molecular weight, for instance glycerol or a glycol, followed by a purification by crystallization in an alcohol. The invention is useful for industrial preparation of aloin.

Abstract: The invention relates to topical preparations containing one or more compounds chosen from group (A), which consists of vitamin A-acid or its derivatives, combined with one or more compounds chosen from group (B), which consists of ubiquinones and their derivatives and plastoquinones and their derivatives.

Abstract: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2—CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R2 represents a hydrogen atom or a group R1, and both R2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.

Abstract: A therapeutic formulation comprises a topically acceptable semisolid vehicle and carbamazepine, the vehicle consisting of components that are compatible with the carbamazepine, and the carbamazepine being in a concentration sufficient to permit a therapeutically effective amount of the carbamazepine to be absorbed from the formulation into the skin of a patient. The vehicle may be a cream, ointment, or gel. A method of treating a skin condition of a patient such as psoriasis comprises applying carbamazepine topically to the patient's skin until the condition improves. A method of administering carbamazepine to a patient comprises applying a formulation comprising carbamazepine topically to the patient's skin.

Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Abstract: The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention relates to a therapeutic agent containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient: wherein R is hydrogen or a halogen. The therapeutic agent for dermatitis according to the present invention effectively and in a dose-dependent manner suppresses antigen-induced swelling in a mouse ear, a recognized animal model for atopic dermatitis, and suppresses the antigen-induced flare-up reaction in mice which occurred with the swelling reaction. In addition, no adverse reaction in the skin are observed.

Abstract: The invention refers to new pharmaceutical preparations for the treatment of psoriasis and condyloma acuminata, and containing podophyllotoxin in combination with a liquid triglyceride.

Abstract: Use of zinc protoporphyrin IX and its salts to reduce the number of eosinophils in tissues, particularly for treating hypereosinophilia such as bronchial asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis.

Abstract: This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: This invention relates to the natural topical treatment of portions of skin of a person afflicted with psoriasis or other skin disorders such as dry skin, eczema, itchy skin, red skin, itchy eczema, inflamed skin, and/or cracked skin for the removal of itch and the restoration of the affected areas of skin to a normal condition. The natural treatment of a skin disorder initially involves formation of a natural ointment from the ingredients identified as chicken and hen herb; ruta herb; pure unsalted natural butter; and pure natural beeswax. The natural ointment is formed by combination of the ingredients which includes heating and stirring. The ointment is then applied twice daily to affected areas of skin until a natural cure of the skin disorder is obtained.

Abstract: The invention relates to a medicament containing mixtures of betasitosterol and phytosterol and/or betasitosterol and its physiological metabolites. Processes were discovered for dissolving betasitosterol, which in itself is difficult to dissolve, in various oils and paraffins and in glycerin, which processes offer new indications for the use of these substances. In addition, the esterification of the betasitosterol with carboxylic acids opens up therapeutic possibilities in asthma, inflammatory intestinal diseases, arterial hypertension, autoimmune diseases of the skin and pain relief which far exceed the currently known range of uses of betasitosterol and phytosterol/betasitosterol mixtures.

Abstract: The staining of skin and clothing incidental to the topical application of anthralin may be avoided or eliminated by: (a) topically applying an anthralin formulation containing a therapeutically effective amount of anthralin to the involved area of the skin; and (b) topically applying a wax formulation to the involved area, wherein the wax formulation comprises a wax. In addition, a powder may be topically applied to the involved area.

Abstract: Improved compositions for treating psoriasis, including a body wash composition, spray composition and cream composition and the use of these novel compositions in a system or method of treating psoriasis.

Abstract: The invention concerns the use of at least one activator of receptors of the PPAR-&ggr; type for preparing a pharmaceutical composition for treating skin disorders related to an anomaly of the differentiation of epidermic cells.

Abstract: The present invention is directed to methods and compositions for treating skin disorders. The present invention is easily administered and can be used for both humans and animals. The compositions of the present invention comprise borate compounds and provide relief from skin disorder symptoms and lesions. Additionally, the present invention can be used to provide long term maintenance of symptom-free skin.

Abstract: This application relates to a material which is suitable for the treatment of atopic disease, non-atopic eczema or psoriasis. The material can be extracted from a freeze-dried decoction of a mixture comprising the following Chinese herbs: Radix Ledebouriella, Fructus Tribuli, Herba Potentilla chinensis, Caulis Clematis armandii, Radix Rehmannia, Radix Glycyrrhiza, Radix Paeonia rubra, Cortex Dictamni radicis, Herba Lopatheri, Spica Schizonepetae. The material comprises one or more of those components present in the freeze-dried decoction which run with Rf values in the ranges 0.00 to 0.100, 0.167 to 0.300, 0.400 to 0.533, 0.700 to 0.833 or 0.900 to 0.967 if the freeze-dried decoction is diluted in aqueous solution and subjected to chromatography on a Whatman 2 cms×55 cms×3 mm cellulose strip for 10 hours using a solvent mixture of butanol, ethanol and water in the proportions 4:1:1.

Abstract: Use of an extract of alchemilla vulgaris, or a fraction or a lyophilizate thereof, or one or more active principles contained in said extract, for inhibiting angiogenesis.

Abstract: The present application relates to cosmetic compositions containing, in a cosmetically acceptable aqueous medium, at least one polyorganosiloxane and an acrylic terpolymer, as well as to the use of these compositions for treating keratinous material, in particular the skin or the hair.

Abstract: A method of treatment for a mammal in need of analgesia from an itching skin comprising applying by directional friction against the skin proximate to the itch a composition consisting essentially of dry elemental iodine in the form of an amorphous condensate. The method is found effective in producing analgesia to the affected skin within 1 to 5 minutes after application.

Abstract: A method for treatment of skin includes topical application of a composition containing a therapeutically effective amount of a 1,3-beta-glucan ether derivative. Such application effectively provides treatment and/or prophylaxis of various skin-related problems, such as neurodermatitis and psoriasis, and reduces the evidence of aging by minimizing wrinkles. In an advantageous embodiment, the glucan ether derivative is present in the composition in a range of concentration of about 0.002% to about 8% by weight. In another embodiment the glucan ether derivative is advantageously carboxymethyl glucan sodium salt.

Abstract: A cosmetic or dermatological composition, comprising: an aqueous phase dispersed in an oily phase with a silicone emulsifying agent, wherein the viscosity of the composition, measured with a Rheomat 180 viscometer at a shear rate of 200 s−1 and at 25° C., ranges from 3 Pa.s (30 poises) to 20 Pa.

Abstract: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2—CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R2 represents a hydrogen atom or a group R1, and both R2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.

Abstract: Compounds of formula (1) are described: wherein L1 is a covalent bond or a linker atom or group; R is a carboxylic acid (—CO2H) or a derivative threof; R6 and R7 which may be the same or different is each an atom or group —L2(Alk2)tL3R12 in which L2, L3, Alk2 and t are as previously defined and R12 is a hydrogen or halogen atom or an —OR9, —NR9R10, —NO2, —CN, —CO2R9, —CONR9R10, —COR9, —N(R9)COR10, —N(R9)CSR10, —SO2N(R9)(R10), —N(R9)SO2R9, —N(R9)CON(R10)(R11), —N(R9)CSN(R10)(R11), —N(R9)SO2N(R10)(R11), or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that R6 and R7 are not both hydrogen atoms and when R7 is a hydrogen atom then R4 and R5 is each a hydrogen or halogen atom or an alkyl, alkoxy or nitro group; and the salts, solvates, hydrates and N-oxides thereof, for use in modulating cell adhesion.

Abstract: Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata and skin cancers are provided, such methods comprising administering a composition having antigenic and/or adjuvant properties. Compositions which may be usefully employed in the inventive methods include inactivated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells, M. vaccae culture filtrate and compounds present in or derived therefrom, together with combinations of such compositions.

Abstract: Compositions based on glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solutions of a glycol or glyceric ester of retinoic acid, preferably in association with the ethyl ester of retinoic acid and with hydroquinone, have been found to be particularly effective, as such or in cream form, in eliminating unsightly skin disorders such as acne, wrinkles, scars, stretch marks, dark spots, etc., and in treating mycotic skin diseases and psoriasis.

Abstract: The invention concerns a coal tar extract with reduced polycyclic aromatic hydrocarbon and benzo(a)pyrene content and a method for obtaining same using two sequentially linked distillation systems. The invention also concerns cosmetic and dermatological preparations containing said resulting coal tar extract.

Abstract: Use of stereoisomeric glycosidic compounds of formula (I) as pharmaceutical agents against psoriasis, compounds therefor and pharmaceutical formulations thereof wherein R1 and R2 are independently selected from —H, —OH, (1) and (2) and related esters and ethers thereto; R3 is selected from —H, (3), (4), (5), (6), (7) and (8) and related esters and ethers thereto; R4 is (9); R5 is selected from the group —CH3, —CHO, —COOH, —CH2OH and related esters and ethers thereto; R6 is selected from —OH, (10), (11), (12), (13) and (14) in the preparation of a medicament for the treatment of disease involving hyperproliferation of dermis cells.

Abstract: A method is disclosed for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C20 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

Abstract: A therapeutic composition having plantain and aloe vera constituents is useful in the treatment of the symptoms of arthritis and other afflictions. The therapeutic composition may have only plantain and aloe vera constituents, wherein the plantain constituent is in a range of approximately 57% to 61% by weight of the therapeutic composition and the aloe vera constituent is in a range of approximately 39% to 43% by weight of the therapeutic composition. The therapeutic composition may have other constituents, such as herbal tinctures, added for various purposes, in which case, the plantain constituent is in a range of approximately 51% to 58% by weight of the therapeutic composition, the aloe vera constituent is in a range of approximately 37% to 39% by weight of the therapeutic composition, and the other constituent is in the range of approximately 5% to 10% by weight of the therapeutic composition.

Abstract: Prophylactic or therapeutic agents for respiratory diseases, allergic diseases, keratosis, and carcinomatous pain, containing Smilax china or a plant analogous thereto as the active ingredient. These agents can improve the condition and predisposition of acute and chronic respiratory diseases, such as acute bronchitis, bronchial asthma, asthmatic bronchitis, chronic bronchitis, pan bronchiolitis and bronchiectasis, allergic diseases, such as atopic dermatitis, pollinosis, allergic rhinitis and allergic conjunctivitis, and keratosis, such as psoriasis, lichen, ichthyosis, furfur, and palmoplantar keratosis without side effects and at the same time can lower serum IgE level on an abnormally high level in a short period of time. After the symptom and predisposition have been improved, these agents can, even after suspension of administration, persistently lower the serum IgE level and in addition can inhibit the recurrence of the symptom.

Abstract: A composition and method of treating cutaneous infection and resulting inflammation in animals known as hot spots and mange, respectively, as well as related veterinarian dermatological conditions. The composition includes L-glutathione and a source of selenium which act synergistically and which are included in a suitable topical carrier for topical application.

Abstract: The treatment is by means of nutritional supplements for the adrenal glands, liver and mast cells. The supplements may include potassium, magnesium, Vit B6, Vit B5, Vit C and EFA. A biological mechanism linking stress and allergies such as hayfever or other perennial or seasonal respiratory allergies is proposed and the effect of the treatment thereon is discussed.

Abstract: A botanical composition for soothing irritated skin and method of producing the composition. The composition includes 90-97% by weight aloe juice; 1-5% by weight grapefruit seed and pulp extract; and 1-5% by weight vegetable glycerine. The aloe juice, grapefruit seed and pulp extract and vegetable glycerine are mixed together to form a liquid mixture for application to and covering the irritated skin. The grapefruit seed and pulp extract preferably has a pH of 3. A fragrance may be added to the composition to provide a desired odor to the composition and oils may be added to the composition for use in hydrating the irritated skin on which the composition is applied. The composition is stored in a spray bottle for creating a mist of the composition when applying the composition to the irritated skin.

Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.

Abstract: The present invention relates to cosmetic or dermatological compositions capable of being applied to the skin, the keratinous fibers, the nails, the semimucous membranes and/or the mucous membranes, and which includes a dendritic polyester polymer having terminal hydroxyl functional groups or the combination of such a polymer with a film-forming polymer. It also relates to methods of cosmetic or dermatological treatment using these compositions as well as the use of the compositions for the preparation of dermatological or cosmetic compositions.

Abstract: The present invention provides a composition of matter which has been demonstrated to be a very effective treatment for acne, seborrheic dermatitis and related skin diseases when applied to and contacted with affected skin areas, while avoiding the disadvantages and complications attendant to more established treatments. The composition comprises a synthetic mixture of salts which, when dissolved in a solvent such as water, is ionically composed primarily of a mixture of sodium and magnesium cations and chloride and sulfate anions, and which is preferably free of added zinc. More specifically, the salt mixture according to the present invention comprises the following range of composition in grams/kilogram of salt mixture in the ionic state, the balance being water of hydration: I.

Abstract: The present invention relates to an antiwrinkle composition that includes, in a physiologically acceptable medium: a dispersion of a film-forming polymeric system containing at least one polymer capable of forming a film permeable to water vapor, having a Young's modulus ranging from 108 to 1010 N/m2 and producing, after application at a concentration of 7% in water and then drying, a retraction of the isolated stratum corneum greater than 1% at a temperature of 30° C. and a relative humidity of 40%, and a dendritic polyester polymer having terminal hydroxyl functional groups.

Abstract: Disclosed are compounds of formula II: wherein A is as defined by the specification. Also disclosed are compositions containing the esters and methods for their use in the regulation of skin atrophy and in the treatment of skin disorders such as dry skin, dandruff, acne and eczema.

Abstract: The invention concerns fatty acids uninterrupted by a methylene group as anti-inflammatory agents in superficial tissues of mammals, more particularly a pharmaceutical or cosmetic topical composition comprising, as an active ingredient, at least one fatty acid uninterrupted by a methylene group corresponding to formula (I), an salt or ester thereof, wherein R1 is a C1-C5 alkyl group and R2 is a C2-C6 alkyl group. Preferably, the fatty acid uninterrupted by a methylene group is 20:3(5,11,14). The fatty acid uninterrupted by a methylene group is also used for preparing a composition for modulating the metabolism of lipids in the superficial tissue of mammals.

Abstract: Disclosed are topical pharmaceutical compositions comprising a pharmaceutically active agent such as a corticosteroid, a diol, cetyl alcohol, glyceryl monostearate, laurocapram, stearyl alcohol, sodium lauryl sulfate and water. Also disclosed is a method for the manufacture of the compositions and methods for treating inflammatory skin conditions with the compositions.

Abstract: Novel compositions containing at least one biologically active component derived from peat or similar composition, methods for their preparation and therapeutic uses for a variety of diseases, injuries, and conditions, including wound healing, pain, itch, inflammation, abnormal cell proliferation, or infections caused by fungal, bacterial, rickettsial or viral agents, psoriasis, allergic and other dermatitis, pruritis, eczema, actinic keratosis and similar conditions. In addition, the compositions can be used as diuretics, antiarrhythmics, and cardiac-stimulating agents, as well as for the treatment of mammalian diseases and disorders, including multiple drug resistance, cancers, asthma, rheumatoid arthritis, pain, wound healing, fungal disorders, and other inflammatory disorders. The compositions are derivable from peat or peat-related substances and may alternatively be synthetically produced.

Abstract: Hydrazine derivatives of the formula wherein R1 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R2 represents heterocyclyl or NR5R6, R3 represents hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl or aryl-lower alkyl, R4 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula -Z-aryl, -Z-heterocyclyl or —(CH2)n—, CH═CR7R8, R5 and R6 each independently represent hydrogen or lower alkyl, R7 and R8 each independently represent hydrogen or lower alkyl or R7 and R8 together represent lower alkylene in which one CH2 group is optionally replaced by a hetero atom, X and Z each repres

Abstract: Method of treating or ameliorating symptoms of T-cell mediated disease wherein a composition comprising a therapeutically effective amount of a polyunsaturated fatty acid and a pharmaceutically acceptable carrier is administered to the patient. The polyunsaturated fatty acid contains 18-25 carbon atoms, 1-6 double bonds and has 1 or 2 substitutions selected from &bgr; oxa, &ggr; oxa, &bgr; thia and &ggr; thia, based on the fatty acid acyl carbon atom, or the polyunsaturated fatty acid contains 16-26 carbon atoms, 3-double bonds and is covalently coupled at the carboxylic acid group to an amino acid.